Excited to share our collaborative work on identifying CART targets for pediatric cancer by exon level expression

nature.com/articles/s4146…
St. Jude St. JudeResearch Nature Portfolio

💉 Overcoming T-cell inhibition via the PD-1/PD-L1 axis is a critical challenge in CAR-T cell therapy 📝 Our latest publication in Nature Communications unveils how CAR-antigen affinity could pivotally influence T-cell susceptibility to this axis ⬇️

Safety and anti-tumor activity of autologous Her2 CART in sarcoma. Congratulations Nabil, Meena and the extended team Center for Cell and Gene Therapy and beyond
nature.com/articles/s4301…

🚨We are hiring a Research Assistant to help us supercharge CAR T cells!

Candidates of all experience levels are encouraged to apply. Some lab experience is required, mouse experience is preferred. 2-year minimum commitment.

Please retweet!

Apply here: chop.wd5.myworkdayjobs.com/CHOPExternalCa…

ACGT Research Fellows, and members of the ACGT Scientific Advisory Council, Carl June, MD (Penn), and Michel Sadelain, MD, PhD (@MSKCancerCenter), received the Breakthrough Prize for Life Sciences on Saturday!

(1/3)

Can precision medicine based ex vivo drug screens using patient samples work for children? This study demonstrates that the answer may be yes. nature.com/articles/s4159…

An inhibitory ligand acts directly on CD3e to regulate T cell activation, and disruption of the interaction boosts tumor-specific T cell cytotoxicity to limit tumor growth Cell
cell.com/cell/fulltext/…

What a fantastic story! That's how science should be done.

Not all beneficial TFs show up in transcriptomic analyses as some are regulated post-translationally. A great example of that is FoxO1 which was uncovered by ATAC-Seq. Beautiful work by Evan Weber and teams at Penn and Stanford - huge congratulations 👏

Congratulations Anthony Maresso Joseph Petrosino BCMHouston !

Welcome to Center for Cell and Gene Therapy Dimi! Will look forward to doing cool stuff together 🤓

T-cell lymphoma: the CAR-T revolution is coming
ow.ly/i4bK50R4weV #clinicaltrialsandobservations

An antibody–drug conjugate that could kill TRBC1+ cancer cells in vitro and cure human T cell cancers in mouse models nature Tushar Nichakawade
nature.com/articles/s4158…

Twitter fam! We are looking for a research associate to join our awesome team. If you know anyone interested in the interface of protein engineering, structural bio, gene editing and T cell immunotherapy please reach out! Also, please retweet and spread the word!

Synthetic costimulatory receptor to boost TCR T cells nature.com/articles/s4301…

Will this supersede library screenings soon?
biorxiv.org/content/10.110…

Best way to start a week: Our story on CD3-zeta gene editing to create CAR-T and CAR-NK cells is online at Blood Journal 🩸 🧬 🙌

Thanks to the entire team led by Jonas Kath and all collaborators! 🙏

ashpublications.org/blood/article/…

I have been waiting >1 year to see this manuscript by Steven Highfill, Hannah W. Song, Ph.D. et al published. Out today in Cytotherapy, the effect of different manufacturing platforms on CART differentiation. 👏👏👏. Would love to see more like this!!!

isct-cytotherapy.org/article/S1465-…